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Research Article
PARP-1 regulates DNA repair factor availability
Matthew J Schiewer1,2,*, Amy C Mandigo1,2, Nicolas Gordon1,2, Fangjin Huang3, Sanchaika Gaur3,
Renée de Leeuw1,2, Shuang G Zhao4, Joseph Evans4, Sumin Han4, Theodore Parsons2,5, Ruth Birbe6,
Peter McCue2,5, Christopher McNair1,2, Saswati N Chand1,2, Ylenia Cendon-Florez1,2, Peter Gallagher1,2,
Jennifer J McCann1,2, Neermala Poudel Neupane1,2, Ayesha A Shafi1,2, Emanuela Dylgjeri1,2,
Lucas J Brand1,2, Tapio Visakorpi7, Ganesh V Raj8, Costas D Lallas2,9, Edouard J Trabulsi2,9,
Leonard G Gomella2,9, Adam P Dicker2,10, Wm. Kevin Kelly2,11, Benjamin E Leiby2,12,
Beatrice Knudsen3 , Felix Y Feng13 & Karen E Knudsen1,2,9,10,11
Abstract
PARP-1 holds major functions on chromatin, DNA damage repair
and transcriptional regulation, both of which are relevant in the
context of cancer. Here, unbiased transcriptional profiling revealed
the downstream transcriptional profile of PARP-1 enzymatic activ-
ity. Further investigation of the PARP-1-regulated transcriptome
and secondary strategies for assessing PARP-1 activity in patient
tissues revealed that PARP-1 activity was unexpectedly enriched as
a function of disease progression and was associated with poor
outcome independent of DNA double-strand breaks, suggesting
that enhanced PARP-1 activity may promote aggressive pheno-
types. Mechanistic investigation revealed that active PARP-1
served to enhance E2F1 transcription factor activity, and specifi-
cally promoted E2F1-mediated induction of DNA repair factors
involved in homologous recombination (HR). Conversely, PARP-1
inhibition reduced HR factor availability and thus acted to induce
or enhance “BRCA-ness”. These observations bring new under-
standing of PARP-1 function in cancer and have significant ramifi-
cations on predicting PARP-1 inhibitor function in the clinical
setting.
Keywords DNA repair; E2F1; PARP; transcription
Subject Category Cancer
DOI 10.15252/emmm.201708816 | Received 22 December 2017 | Revised 10
October 2018 | Accepted 25 October 2018 | Published online 21 November 2018
EMBO Mol Med (2018) 10: e8816
Introduction
Poly(ADP-ribose) polymerase 1 (PARP-1) is a multifunctional
protein of importance in cancer. PARP-1 is an abundantly expressed
nuclear enzyme which uses NAD+ as a substrate to poly(ADP-
ribose)-ylate (PARylate) nuclear proteins, including automodifi-
cation of PARP-1 itself (D’Amours et al, 1999; Krishnakumar &
Kraus, 2010). PARP-1 plays a key role in several key biological
processes: replication fork stability (Bryant et al, 2009), cell death
(Yu et al, 2002), DNA repair and genomic stability (Durkacz et al,
1980), telomere maintenance (Beneke et al, 2008), chromatin orga-
nization (Poirier et al, 1982), and transcriptional regulation (Kraus
& Lis, 2003; Schiewer & Knudsen, 2014).
The DNA repair functions of PARP-1 have been targeted for anti-
cancer effects through use of pharmacological PARP inhibitors
(PARPi; Lord & Ashworth, 2008), which have been approved of
ovarian cancer, and are under clinical investigation in a number of
other tumor types, including prostate cancer (PCa). It is thought that
PARPi are especially effective in tumors that lack homologous
recombination (HR) capacity through loss-of-function mutations in
BRCA1 or BRCA2, in a phenomenon termed synthetic lethality
(McCabe et al, 2006; Lord & Ashworth, 2017). However, clinical
trial data in BRCA1/2 mutant-selected tumors indicate that objective
response rates are only ~ 40%, suggesting that BRCA1/2 mutation is
not sufficient for PARPi response (Fong et al, 2009; Audeh et al,
2010; Gelmon et al, 2011; Kaye et al, 2012; Sandhu et al, 2013;
Coleman et al, 2015). Additionally, a recently published clinical trial
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combining PARPi and androgen receptor (AR)-directed therapy in
patients with advanced PCa demonstrated clinical benefit, irrespec-
tive of HR status (Clarke et al, 2018). Furthermore, the TO-PARP
trial (Mateo et al, 2015) led to FDA Breakthrough Status for patients
with BRCA2 or ATM mutant castration-resistant prostate cancer
(CRPC). Olaparib responders were enriched for defects in DNA
repair genes, such as biallelic loss of BRCA2 and ATM. However,
while most responders (14/16) in this trial were categorized as
biomarker positive for HR deficiency, the biomarker suite included
single copy loss of DNA repair factors, as well as alterations to
HDAC2, which is involved in transcriptional repression (Rountree
et al, 2000). While these studies that not all PARPi responders with
PCa harbor HR-defective tumors, and not all PCa tumors that exhibit
aberrant DNA repair are PARPi responsive, there is clinical evidence
that PARPi resistance is associated with restored HR function in
multiple tumor types (Edwards et al, 2008; Barber et al, 2013;
Christie et al, 2017; Kondrashova et al, 2017; Pishvaian et al, 2017;
Weigelt et al, 2017), including PCa (Goodall et al, 2017; Quigley
et al, 2017). Additionally, PARPi resistance has been associated
with differential DNA damage response (DDR) network functioning
(Jaspers et al, 2013; Johnson et al, 2013; Gogola et al, 2018). These
mechanisms of resistance to PARPi indicate that for these tumors,
DDR defects likely led to PARPi responses. These clinical findings
indicate that further mechanistic understanding of PARP-1 functions
is needed to develop useful clinical biomarkers of response to
PARPi.
Given the potential implications of PARP-1-mediated functions in
human malignancies, and the need for biomarkers of PARPi
response, it was imperative to discern the molecular basis of PARP-
1 function and activity in the context of BRCA1/2 wild-type PCa,
and determine the contribution of PARP-1-mediated transcriptional
events on tumor phenotypes.
Results
PARP-1 enzymatic activity is increased as a function of disease
progression and is associated with poor outcome
To ascertain the impact of PARP-1 function on aggressive tumor
behavior, PCa was utilized as a disease system. In this tumor type,
the role of PARP-1 in transcriptional regulation of key transcription
factors of PCa relevance has been demonstrated (ETS transcription
factors and androgen receptor (AR); Brenner et al, 2011; Schiewer
et al, 2012), and AR is a key driver of PCa initiation and progres-
sion. Furthermore, PARPi has generated promising clinical trial data
in advanced PCa (Mateo et al, 2015). Initially, human tissues from
primary, hormone therapy (HT)-sensitive PCa, and metastatic CRPC
(mCRPC) were queried for PARP-1 enzymatic activity via immuno-
histochemistry (IHC) for PAR (Poly(ADP-ribose), the product of
PARP-1 enzymatic activity; Fig 1A). PARP-1 enzymatic activity was
elevated in mCRPC when compared to primary PCa (Fig 1B). These
data give confirmation of predictions from preclinical models which
showed elevated PARP-1 enzymatic activity in CRPC cell lines (in-
cluding C4-2 and LNCaP-abl) compared to hormone therapy (HT)-
sensitive cell lines (including LNCaP, LAPC4, and VCaP; Schiewer
et al, 2012). To query the impact of elevated PARP-1 enzymatic
activity on clinical outcomes, PARP-1 activity was assessed as a
function of proliferative indices (Appendix Fig S1A) and cT stage at
primary diagnosis (Appendix Fig S1B). No correlation was
observed, indicating that higher PARP-1 activation status is not
simply due to increased cell proliferation or larger volume tumor.
Furthermore, there were no correlations between PARP-1 enzymatic
activity and molecular alterations that are frequent in PCa, including
TMPRSS2:ERG fusion status (Appendix Fig S1C), PTEN score
(Appendix Fig S1D), or AR copy number (Appendix Fig S1E).
However, enhanced PARP-1 activity was significantly associated
with decreased progression-free survival (PFS; Fig 1C). These data
indicate that PARP-1 enzymatic function is not only elevated in
CRPC, but also predictive of PFS, which is associated with disease-
specific mortality.
To expand upon these data, multiplexed quantifiable immunoflu-
orescent IHC was performed on non-neoplastic prostate tissue,
primary PCa, and mCRPC (Fig 1D top left, higher magnification at
right). As measured through quantification of PAR immunoreactiv-
ity, PARP-1 enzymatic activity was elevated in primary PCa (median
value 62.03) as compared to non-neoplastic prostate tissue (median
value 51.52), and highest in mCRPC tissue (median value 69.10;
Fig 1D, bottom left). However, the observed increase in PARylation
during disease progression cannot be simply attributed to total
PARP-1 protein expression, as the ratios of PARP-1 and PAR expres-
sion levels differed across disease states (Fig 1D, bottom middle;
medians of PAR values 51.67, 54.29, and 47.81 for non-neoplastic,
primary PCa, and mCRPC, respectively).
Being intricately involved in DNA damage repair, PARP-1 enzy-
matic activity is induced by DNA damage (Durkacz et al, 1980). To
determine whether the elevated PARP-1 enzymatic activity in
mCRPC observed above was associated with DNA damage repair,
immunoreactivity of cH2AX, a measure of repair of DNA double-
strand breaks (DSBs; Podhorecka et al, 2010), was performed. This
analysis indicated that PARP-1 enzymatic activity as a function of
disease progression was not associated with repair of DSBs (Fig 1D,
bottom right; median values 44.20, 51.80, and 46.20 for non-
neoplastic, primary PCa, and mCRPC, respectively), suggesting that
PARP-1 activity is regulated by other factors in addition to DNA
damage. Dual assessment of DSB repair and PARP-1 activity in each
specimen revealed a positive correlation between PAR and cH2AX
in non-neoplastic prostate tissues (r = 0.2853), and primary PCa
tissues (r = 0.3573), but this association is lacking in mCRPC tissues
(r = 0.03825; Fig 1E), further indicating that elevated PARP-1
enzymatic function in mCRPC is not attributable to increased DNA
DSB repair. Together, these data demonstrate that PARP-1 enzy-
matic activity is heterogeneous, increases as a function of PCa
progression, is not associated with levels of either PARP-1 protein
expression or of DNA damage repair in mCRPC, and may predict
poor outcome in PCa.
Identification of the PARP-1-regulated transcriptome and
relevance for disease progression
As demonstrated above, PARP-1 enzymatic activity is elevated as a
function of PCa progression independent of DNA DSB repair. As
such, other PARP-1 functions were analyzed. To assess PARP-1-
mediated transcriptional regulation in the context of androgen
signaling, hormone therapy-sensitive (HT-sensitive) PCa cells were
deprived of steroids for 72 h, then treated with PARP-1 inhibition
2 of 20 EMBO Molecular Medicine 10: e8816 | 2018 ª 2018 The Authors
EMBO Molecular Medicine PARP-1 impinges on DDR gene expression Matthew J Schiewer et al
AC
D
E
B
Figure 1.
ª 2018 The Authors EMBO Molecular Medicine 10: e8816 | 2018 3 of 20
Matthew J Schiewer et al PARP-1 impinges on DDR gene expression EMBO Molecular Medicine
(or control) followed by 16 h dihydrotestosterone (DHT) stimula-
tion as depicted in Fig 2A (left) to assess the impact of PARP-1
suppression in the presence and absence of AR activity. As
expected, DHT altered the expression of a large number of tran-
scripts (n = 1358), and PARP-1 suppression resulted in differential
transcript expression when compared to DHT (n = 877; Fig 2A,
right), consistent with previous reports that PARPi alters the tran-
scriptional effects of androgen signaling (Schiewer et al, 2012). This
was further confirmed using a previously characterized set of AR/
DHT-responsive target genes, the majority of these genes are oppo-
sitely regulated by DHT and PARPi in LNCaP (Appendix Fig S2A).
PARP-1 has also been found to regulate castration-resistant AR func-
tion (Schiewer et al, 2012). To assess the overall transcriptional
effects of PARP-1 in an unbiased manner in the context of CRPC,
C4-2 cells were deprived of steroids for 72 h, then were either
treated PARPi (or control) as depicted in Fig 2B (left) for 16 h. In
total, 2011 transcripts were differentially regulated upon PARPi
treatment when compared to control in CRPC cells, thus defining a
PARP-1-regulated transcriptome in CRPC. The overlap of differen-
tially regulated genes in HT-sensitive vs. CRPC cells was derived,
and the data indicate there are both overlapping and distinct tran-
scriptional changes elicited by each condition and in the individual
cell lines (Appendix Fig S2B). Gene lists are included in Dataset
EV1. These data indicate that there may be a core transcriptional
program regulated by PARP-1 in PCa cells, which includes a large
number of DHT-responsive genes (n = 169), but the transition to
castration resistance likely expands the relevance of PARP-1-regu-
lated transcription, given the larger number of transcripts that are
altered upon PARPi (n = 1,810 unique genes regulated by PARP-1).
Importantly, the transcripts associated with active PARP-1 (down-
regulated by PARPi) in both HT-sensitive and CRPC cells signifi-
cantly increased in expression from benign tissues, to primary PCa,
to PCa metastases (Fig 2C) when these transcripts were queried
against a publically available data set (Grasso et al, 2012). Further-
more, these data were validated using other publically available
data sets (Lapointe et al, 2004; Taylor et al, 2010; Yu et al, 2007;
Appendix Fig S3), thus indicating that the PARP-1-responsive tran-
scriptome is elevated as a function of PCa progression. Together
with immunohistochemical PARP-1 activity assessment (Fig 1),
these collective data indicate that both PARP-1 enzymatic activity
and PARP-1-sensitive transcriptional events are enhanced as a func-
tion of disease progression.
PARP-1 regulates pro-oncogenic transcription factor signaling
To assess the potential biological consequences of the observed
transcriptional enhancement of PARP-1, Gene Set Enrichment Anal-
ysis (GSEA; Mootha et al, 2003; Subramanian et al, 2005) Molecular
Signatures Database (MSigDB) analyses were performed using the
unbiased data generated as described above. Utilizing the generaliz-
able KEG MSigDB demonstrated an enrichment for cell cycle-related
and DNA damage repair-associated pathways (including homolo-
gous recombination; Fig 3A, left). Analyses using the more specific
Hallmarks MSigDB confirmed previous studies, in that the Androgen
Response hallmark was enriched in and suppressed in CRPC cells
(NES = 2.54; Fig 3A, right bottom). The statistically highest
enriched MSigDB hallmark was E2F Targets (HT-sensitive
NES = 1.51, CRPC NES = 3.31; Fig 3A, right top), which has
canonical roles in the regulation of both the cell cycle and DNA
damage repair (Biswas & Johnson, 2012). These data indicate that
in addition to playing a key role in AR transcriptional activity,
PARP-1 transcriptionally regulates processes associated with the cell
cycle and DNA damage repair.
The E2F family of transcription factors regulate critical processes
of importance in cancer, including cell cycle regulation, DNA repair
(Biswas & Johnson, 2012), mitochondrial function (Goto et al,
2006), cell death (Polager & Ginsberg, 2009), tumor progression and
metastatic development (Alla et al, 2010), stemness (Chen et al,
2008, 2009), and angiogenesis (Qin et al, 2006). E2F1 is frequently
deregulated in PCa (Sharma et al, 2010), and deregulated E2F1
activity is associated with aggressive disease (McNair et al, in press,
JCI). For validation, both HT-sensitive and CRPC cells were treated
as depicted in Fig 2A and B above, RNA was extracted, and
subjected to qPCR for canonical E2F1 target genes (E2F1, PCNA,
MCM7, and CCNA2). As shown, each of these transcripts was dimin-
ished by treatment with the PARPi veliparib by 40–60% in both the
context of HT-sensitive (Fig 3B, top) and CRPC cells (Fig 3B,
bottom). Confirmation that these genes are E2F1 target genes was
conducted by transiently knocking down E2F1, and subsequent
gene expression analyses (Appendix Fig S4A). To explore the impact
of exogenous E2F1 expression on PARP-1-regulated E2F1 activity,
models of exogenous E2F1 were generated. Upon examination of
E2F1 target gene expression after PARP inhibition (Appendix Fig
S4B), it was determined that E2F1 target gene expression is no
longer under the control of PARP-1. These data indicate that
◀ Figure 1. PARP-1 enzymatic activity is increased as a function of disease progression and is associated with poor outcome.A Tissue microarrays (TMAs) from primary PCa (n = 132) and CRPC (n = 148) were stained via immunohistochemistry for poly(ADP-ribose; PAR), and scored by a clinical
pathologist (T. Parsons) for intensity (0–3) and percentage (0–3).
B PAR score was generated via the equation: (intensity × 1) + (percentage × 2). PAR scores were compared between primary and CRPC. ****P value < 0.0001 by
Chi-square test.
C Manual PAR scores were divided in to quartiles and then were compared to progression-free survival in the CRPC TMAs. *P < 0.05, ns = not statistically significant
by Log-rank (Mantel-Cox). 1st quartile vs. 2nd quartile, P = 0.1482; 1st quartile vs. 3rd quartile, P = 0.5794; 1st quartile vs. 4th quartile, P = 0.0160; 2nd quartile vs.
3rd quartile, P = 0.3869; 2nd quartile vs. 4th quartile, P = 0.2110; 3rd vs. 4th quartile, P = 0.0201. 1st quartile (n = 24); 2nd quartile (n = 22); 3rd quartile (n = 27);
4th quartile (n = 26).
D Top left: Representative image of one TMA core after multiplex fluorescent IHC for cH2AX (green), PAR (red), PARP-1 (purple), with DNA (blue). Top right: Insets of
parent image on the left. Numbers above inset columns coincide with numbers on image at left that were chosen for further magnification and representation (boxed
areas). Bottom left: Percent positive staining for PAR for the entirety of each TMA cohort. Bottom middle: Percent positive staining for PARP-1. Bottom right: cH2AX for
the entirety of each TMA cohort. Data were considered after a median intensity cutoff and analyzed for statistical significance using two-tailed Student’s t-test for
PAR, PARP-1, and cH2AX, respectively. Exact P values are indicated. Horizontal lines are median. Box limits are 25% and 75% percentiles, and whiskers are min to max.
E Two-tailed Spearman correlation test between PAR and cH2AX (% positive with a median intensity cutoff). Exact P values are indicated when available.
Source data are available online for this figure.
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exogenous expression of E2F1 results in loss of E2F1 regulation by
PARP-1. As such, amplified E2F1 may serve as exclusion criteria in
future clinical investigation of PARPi in PCa. These data indicate
that canonical E2F1 target gene expression is sensitive to PARP-1
function.
To assess the impact of PARP-1 on E2F1 function, chromatin
immunoprecipitation (ChIP) analyses were performed. In conditions
that were identical to those utilized for the transcriptome analyses
in Fig 2, these ChIP analyses indicate that PARP-1 suppression
resulted in diminished E2F1 at the E2F1 locus by ~ 40% (Fig 3C,
top left). This is important, given that E2F1 is a regulator of E2F1
gene expression. Additionally, PARP-1 was found at the E2F1 locus,
and PARP-1 residency at this locus was reduced ~ 50% in response
to PARPi (Fig 3C, top right). Furthermore, RNA polymerase II resi-
dency was reduced by ~ 50%, as was the active transcriptional
mark, acetylated histone H4 by ~ 66% (Fig 3C, bottom). These data
indicate that PARP-1 enzymatic activity is involved in the biochemi-
cal regulation of E2F1 transcriptional function on chromatin.
A
B
C
Figure 2. Identification of the PARP-1-regulated transcriptome and relevance for disease progression.
A Left: Schematic representing the conditions utilized for transcriptomic analyses (n = 2) of HT-sensitive LNCaP cells. Cells were deprived of hormones for 72 h, followed
by either treatment with 2.5 lM veliparib (PARPi) or vehicle control (DMSO) for 1 h, then subsequently treated with either 1 nM DHT or vehicle control (EtOH) for
16 h. Middle: Immunoblot with the indicated antisera. Right: Volcano plots of transcripts found to be differentially regulated by DHT vs. EtOH (left) or DHT vs. PARPi
followed by DHT (right). Red dots indicate transcripts that were both statistically significantly altered (P < 0.05) and more than 1.5-fold changed.
B Left: Schematic representing the conditions utilized for transcriptomic analyses (n = 2) of CRPC C4-2 cells. Cells were deprived of hormones for 72 h, followed by
either treatment with 2.5 lM veliparib (PARPi) or vehicle control (DMSO) for 16 h. Middle: Immunoblot with the indicated antisera. Right: Volcano plots of transcripts
found to be differentially regulated PARPi vs. vehicle control. Red dots indicate transcripts that were both statistically significantly altered (P < 0.05) and more than
1.5-fold changed.
C Genes found to be down-regulated by PARPi as described above (P value < 0.05, 1.5-fold change) in either HT-sensitive cells (left) or CRPC cells (right) were queried
against the expression of these genes in the Grasso et al data set in Oncomine. Benign = gray, primary PCa = blue, metastases = orange. Boxplot was generated
using the mean expression of the PARPi down-regulated genes in the indicated data sets. Statistical significance determined by two-tailed Student’s t-test. Box plots
are median and upper and lower quartiles. Whiskers are min and max. For the Grasso et al data set, n = 28 benign prostate tissues, n = 59 localized prostate cancer,
and n = 35 metastatic castration resistant.
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To assess the impact of PARP-1 on E2F1 function in vivo,
CRPC (C4-2) xenografts were generated in castrated, immunocom-
promised mice. Tumor-bearing mice were then treated with the
PARPi veliparib for 72 h, sacrificed, and tumors were excised. As
shown, the expression of canonical E2F1 target genes (E2F1, PCNA,
MCM7, and CCNA2) was diminished in vivo upon PARP-1 suppres-
sion (Fig 3D). To further validate these findings, human tissues
were utilized for an explant protocol that has been previously
described (Centenera et al, 2012, 2013; Schiewer et al, 2012;
Comstock et al, 2013; Goodwin et al, 2015; de Leeuw et al, 2015;
Hartsough et al, 2018). Briefly, fresh human PCa samples are
obtained at the time of surgical resection, subdivided, and cultured
ex vivo under conditions that retain the glandular architecture, stro-
mal content, and clinicopathologic features of the original tumor.
Explants were exposed to PARPi (or control), and the expression of
canonical E2F1 target genes (E2F1, PCNA, MCM7, and CCNA2) was
assessed. As shown, the response was heterogeneous, but these
patient tissues demonstrated significantly diminished E2F1 target
gene expression in response to PARPi (Fig 3E). These collective data
identify PARP-1 as a major effector of E2F1 function in vitro,
in vivo, and in human PCa tissues.
PARP-1 effects on E2F signaling are independent of cell cycle
phase and distinct from those elicited by CDK4/6 inhibition
To assess the impact of cell cycle phase on PARP-1-mediated
E2F1 regulation, HT-sensitive and CRPC cells were treated using
conditions identical to those described in Fig 2, and subjected to
a BrdU pulse and FACS analyses. As shown, there was no change
in DNA replication at an early time point (3 h) or at the time
point at which the transcriptional effects of PARP-1 were assessed
(16 h; Fig 4A), indicating that cell cycle phase cannot explain the
decrease in E2F1 function after PARP-1 suppression, although at
later time points, DNA replication is diminished upon PARPi.
While E2F1 itself cannot currently be therapeutically targeted, the
upstream kinases that positively regulate E2F1 function (cyclin-
dependent kinases 4 and 6, CDK4/6) can be inhibited (O’Leary
et al, 2016), and CDK4/6 inhibitors (CDK4/6i) are under clinical
investigation for a number of tumor types, including PCa
(NCT02905318, NCT02494921, NCT02555189). The analyses
above indicate that E2F function is under the control of PARP-1,
and thus, it was necessary to compare the transcriptional effects
of CDK4/6i to PARPi to discern the transcriptional effects of
PARP-1. To accomplish this, unbiased transcriptomic data gener-
ated in HT-sensitive cells treated with either the CDK4/6i palboci-
clib or the PARPi veliparib were compared. As shown in Fig 4B,
left, there was no significant overlap in the genes up-regulated by
CDK4/6i and PARPi (n = 1), and minimal overlap in the genes
down-regulated by each treatment (n = 45). However, these anal-
yses indicate that the genes specifically down-regulated by PARPi
were not only the most abundant (n = 157), but GSEA MSigDB
analyses indicate this gene set was enriched for DNA repair
processes, including HR (Fig 4B, right). These data indicate that
PARP-1 regulates a cell cycle-independent E2F1 function, distinct
from the transcriptional gene regulation by E2F associated with
cell cycle control.
PARP-1 controls of HR factor availability are associated with
modulation of the chromatin context of E2F1 function
As the data above identify PARP-1 as a positive regulator of E2F1
activity and subsequent expression of genes controlling HR, the
impact of PARP-1 inhibition was compared to that of HR deficiency.
Utilizing the HR gene set to generate heatmaps from the unbiased
data derived above in Fig 2, it was determined that whether the
comparator was DHT in HT-sensitive cells, or vehicle control in
CRPC cells, the majority of HR gene expression was diminished with
PARPi (Fig 5A, left). In fact, the majority of genes involved in most
DNA repair pathways declined after PARPi treatment (Appendix Fig
S5). Furthermore, comparison of the unbiased data generated above
with a previously developed HR deficiency transcriptional signature
(Peng et al, 2014) demonstrated a significant overlap in both
down-regulated (n = 104/151) and up-regulated (n = 44/89) genes
(Fig 5A, middle). This signature was generated by independently
silencing BRCA1, RAD51, or BRIT1, followed by unbiased transcrip-
tomic profiling. The intersection of these conditions serves as the
HR deficiency transcriptional signature. This intersection proved to
be statistically significant using GSEA analyses (Fig 5A, right).
These data suggest PARP-1 suppression reduces availability of HR
factors by transcriptional regulation.
◀ Figure 3. PARP-1 regulates pro-oncogenic transcription factor signaling.A Left: Data generated as described above in Fig 2 were utilized for Gene Set Enrichment Analysis (GSEA) Molecular Signature DataBases (MSigDB) KEGG analyses.
Cutoff for reporting was a false discovery rate q value of < 0.25, and normalized enrichment scores (NES) are shown, with darker colors indicating more enrichment.
Middle: Data generated as described above in Fig 2 were utilized for Gene Set Enrichment Analysis (GSEA) Molecular Signature DataBases (MSigDB) KEGG analyses.
Cutoff for reporting was a false discovery rate q value of < 0.25, and normalized enrichment scores (NES) are shown, with darker colors indicating more enrichment.
Open circles indicate cell cycle-related hallmarks, and closed circles indicate DNA damage repair-related hallmarks. Right: Selected GSEA MSigDB Hallmarks pathways
are shown with NES and false discovery rate (FDR).
B Indicated cell lines were treated as depicted in Fig 2. Data are depicted as mean  standard deviation of three independent biological experiments. Statistical
significance was determine by two-tailed Student’s t-test where *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. LNCaP: E2F1, P = 0.0159; PCNA, P = 0.0217;
MCM7, P = 4.0936e-6; CCNA2, P = 0.0005. C4-2: E2F1, P = 0.0074; PCNA, P = 0.1258; MCM7, P = 3.7471e-5; CCNA2, P = 0.0031.
C ChIP-qPCR after C4-2 cells were treated as depicted in Fig 2. Data are depicted as mean  standard deviation of three independent biological experiments. Statistical
significance was determined by two-tailed Student’s t-test where *P < 0.05, ****P < 0.0001. E2F1 ChIP, P = 0.4610; PARP-1 ChIP, P = 0.1773; Pol II ChIP, P = 0.0305;
AcH4 ChIP, P = 7.4261e-5.
D Athymic nude mice were injected with C4-2 cell mixed with matrigel. Once tumors became 100 mm3, mice were treated with either vehicle control or veliparib.
Seventy-two hours later, tumors were harvested, RNA was isolated and used for qPCR quantification of the indicated transcripts. Data are depicted as log2 absolute
gene regulation of veliparib samples compared to control samples,  standard deviation of three independent xenograft tumors.
E Prostatectomy tissue (n = 6) was cultured as previously described, and treated with either vehicle control or veliparib for 6 days. RNA was then harvested from the
tissues and used for qPCR quantification of the indicated transcripts. Data are depicted as log2 absolute gene regulation of veliparib samples compared to control
samples. Each individual tissue is depicted by a separate bar color. Statistical analyses were performed by Wilcoxon signed rank test.
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The impact of PARP-1 activity on the expression of HR genes
was validated at the transcript level (~ 20–50% reduction; Fig 5B,
left) and at the protein level (~ 15–80% reduction) in vitro (Fig 5B
right). Validation that these HR genes are E2F1-regulated was
accomplished by transiently knocking down E2F1 and examining
HR gene expression (Appendix Fig S6A). Transcriptional regulation
of HR gene expression was found to be conserved across all PCa/
CRPC models tested (Appendix Fig S6B). Furthermore, the depen-
dence of HR gene expression on PARP-1 enzymatic activity was vali-
dated in vivo (Fig 5C). Additionally, utilizing the patient tissue
explant process described in Fig 3 in which prostatectomy tissues
are cultured in the laboratory, the reliance of HR gene expression on
PARP-1 enzymatic function could be further explored. PARPi thus
elicited a more robust and significant decrease of HR gene expres-
sion, than canonical E2F1 target genes as described above, but still
with patient heterogeneity of response (Fig 5D). Together, these
data indicate that PARP-1 inhibition reduces expression of many
genes involved in DNA repair (especially HR), suggesting that
inhibiting PARP-1 enzymatic function may transcriptionally induce
a state of “BRCA-ness”, or relative HR deficiency.
To define potential mechanism(s) by which PARP-1 regulates HR
gene expression, ChIP-qPCR experiments were performed at regula-
tory loci of HR genes known to be regulated by E2F1. While there
was no clear pattern of altered E2F1 residency at three HR gene loci
(BRCA2, RAD51, and TOP2A) after PARPi (Fig 5E, top left graphs),
in each case, PARP-1 was found to reside at each locus, and this
residency was diminished upon PARPi by ~ 60–83% (Fig 5E, top
right graphs). Thus, PARPi destabilizes PARP-1 function at HR gene
regulatory loci, likely compromising E2F1 activity. As would be
expected, RNA polymerase II and acetylated histone H4 levels were
diminished at these HR gene loci in response to PARPi by 40–80 and
28–60%, respectively (Fig 5E, bottom left and right graphs, respec-
tively). Furthermore, it was determined that PARPi alters the activa-
tion status the endogenous inhibitor of E2F1 function, the
retinoblastoma tumor suppressor (RB; Fig 5F), wherein PARPi
resulted in enrichment of hypophosphorylated (active) RB, suggest-
ing that the functions of PARP-1 suppression may be pleiotropic.
Additionally, based on the observed decrease in the active acety-
lated histone H4 mark upon PARPi in Fig 5E, it was determined that
this was associated with reduced CBP chromatin occupancy
(Fig 5G). These congruous data are important, as CBP is a key
histone acetyltransferase with known functions in PCa (Santer et al,
2011; Ianculescu et al, 2012). Combined, these data indicate that
PARP-1 not only resides at HR gene regulatory loci and is dimin-
ished upon PARPi, but PARP-1 enzymatic activity appears to
support E2F1 in the context of a coactivator, whose functions
include modulation of RB.
Altered HR factor expression is prevalent in human PCa and is
enriched during disease progression
Data herein indicate that PARP-1 positively regulates E2F1-mediated
HR gene expression in cancer, and that suppression of this activity
can potentially induce a “BRCA-ness” phenotype. Given that PARP-
1 activity is enhanced as a function of aggressive disease, patterns
of HR gene expression were queried in human cancer. An assess-
ment of the TCGA data set (Cancer Genome Atlas Research N,
2015), which includes only primary PCa, demonstrated that when
both RNA and DNA alterations are taken in to account, 50.45% of
tumors in this data set harbored altered HR gene RNA or DNA
(Fig 6A, left). The most frequent HR gene alteration found in
primary disease was mRNA up-regulation (65%), while mutations
only occurred in 6% (Fig 6A, right). Utilizing the portion of the
TCGA data set (Cancer Genome Atlas Research N, 2015) with
matched normal and primary PCa tissues, several HR genes were
significantly up-regulated in cancer (Fig 6B), suggesting that deregu-
lation of HR gene expression occurs during PCa tumorigenesis.
Genes that either did not pass the cutoff for statistical significance or
did not increase are shown in Appendix Fig S7. In the PCF-SU2C
data set of advanced mCRPC tumors (Robinson et al, 2015), there
was an increased occurrence of HR gene defects, with 68% of
tumors harboring either DNA or mRNA alterations (Fig 6C, left).
The most frequent alteration was mRNA up-regulation (71%), while
only 10% of these tumors harbored mutations in these HR genes
(Fig 6C, right). These observations were supported by two other,
independent data sets (Kumar et al, 2016; Taylor et al, 2010;
94.74% HR gene alteration (Appendix Fig S8, top left), 76% of
which was mRNA up-regulation (Appendix Fig S8, top right);
67.65% HR gene alteration (Appendix Fig S8, bottom left), 26% of
which was mRNA up-regulation (Appendix Fig S8, top right),
respectively). However, the most frequent gene alteration in the
second data set was gene amplification, not mutation, further
suggesting that HR gene up-regulation is the predominant alteration
present in human PCa. Assessment of individual tumor-level data
indicates that HR alterations are not mutually exclusive, and the
most frequently altered HR gene is NBN (22%), while BRCA1 and
BRCA2 are altered in ~ 7 and 8% of these tumors, respectively
(Fig 6D). Several studies have indicated that the frequency of DNA
repair gene mutations is elevated in advanced PCa when compared
to primary disease (Grasso et al, 2012; Robinson et al, 2015;
Pritchard et al, 2016). Data presented herein confirm this and also
indicate that HR gene expression is also increased as a function of
PCa progression. Combined, these data not only reiterate that HR
gene defects occur at a higher frequency in advanced PCa, but the
most frequent HR gene aberration is mRNA up-regulation, rather
◀ Figure 4. PARP-1 effects on E2F signaling are independent of cell cycle phase and distinct from those elicited by CDK4/6 inhibition.A Indicated cell lines were treated as depicted in Fig 2, and labeled with bromodeoxyuridine (BrdU), harvested at indicated time points and utilized for FACS analyses.
Data are depicted as mean  standard deviation of three independent biological experiments. *P < 0.05 as determined by two-tailed Student’s t-test. LNCaP: 3 h,
P = 0.9838; 16 h, P = 0.2197, 24 h, P = 0.0207. C4-2: 3 h, P = 0.4520; 16 h, P = 0.9446; 24 h, P = 0.4025; 48 h, P = 0.3431.
B Top: Data generated as described above in Fig 2 were compared to a separate microarray analysis in which the same cell line was exposed to 1 lM palbociclib
instead of veliparib. Cutoffs for comparison were a P value < 0.05, and fold change of 1.5. Venn diagrams shows the overlapping and non-overlapping genes of both
down- (top) and up-regulated (bottom) genes in response to either treatment modality. Statistical significance was determined using the Chi-squared statistical test.
Bottom: Genes found to be exclusively regulated by palbociclib, commonly regulated by palbociclib and veliparib, or exclusively regulated by veliparib were used for
Gene Set Enrichment (GSEA) KEGG pathway analyses. Data indicate both FDR q value, where the darker colors indicate higher confidence (lower q). Numbers indicate
q values. Blue arrow highlights the Homologous Recombination KEGG pathway.
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than mutation. HR gene defects increase during prostate cancer
progression, the most frequent of these defects is mRNA up-regula-
tion. Since the data presented herein demonstrate that HR gene
expression is controlled by PARP-1, and that PARP-1 enzymatic
activity is increased during prostate cancer progression, there is an
association between PARP-1 activity and HR gene expression. These
data identify HR gene deregulation as a common feature in
advanced disease, further highlighting the potential importance of
altered HR gene expression in disease development and/or
progression.
PARP-1 regulates DNA repair factor availability and DNA
repair competency
Based on the fact that PARP-1 transcriptionally regulates HR gene
expression, and that the HR gene mRNA up-regulation that
frequently occurs in advanced disease is meaningful for the
response to PARP-1 inhibitors, it was imperative to assess the
impact of exogenous expression of HR factors on functional and
biological outcomes after PARP-1 suppression. To accomplish this,
multiple model systems were transduced to ectopically express the
HR factors BRCA1 and BRCA2, followed by PARP-1 suppression and
molecular and cellular readouts as depicted in the schematic in
Fig 7A, top. Control transfected cells exhibited reduced cell prolifer-
ation in response to PARP-1 suppression (Fig 7A, bottom, white
bars). However, these same cell lines first transduced to over-
express either BRCA1 or BRCA2 displayed no cell growth inhibition
in response to PARP-1 suppression (Fig 7A, bottom, light blue and
dark blue bars). To define the potential mechanism underlying this
lack of biological response to PARP-1 suppression with BRCA1 or
BRCA2 over-expression, cells treated as per Fig 7A for and were
utilized for immunofluorescent detection of cH2AX foci as a
measurement of DNA DSBs. Control transfected cells treated
exhibited an induction of DSBs upon PARP-1 suppression (LNCaP
~ 2-fold; C4-2 ~ 1.5-fold; 22Rv1 ~ 2-fold; Fig 7B, white bars), which
was abolished with over-expression of either BRCA1 or BRCA2
(Fig 7B, light blue and dark blue bars). These data indicate that
expression dosage of HR factors, which are reduced upon PARP-1
inhibition, has the capacity to alter the biological response to PARP-
1 suppression by differential induction of DSBs. While data
presented in Fig 1F indicate that the correlation between DSBs and
PARP activity is loss during disease progression, data in Fig 7B
demonstrate that artificially de-coupling PARP-1 transcriptional
regulation of DNA repair factors renders tumor cells unresponsive
to PARP inhibition, thus demonstrating that transcriptional regula-
tion of DNA repair factors by PARP-1 has an impact on both the
biochemical and the biological response to PARPi.
Combined (as depicted in the schematic in Fig 7C), these analy-
ses reveal that PARP-1 enzymatic and transcriptional functions are
elevated as a function of PCa progression, and that the PARP-1-regu-
lated transcriptome includes key oncogenic transcription factors.
Furthermore, PARP-1 plays both direct roles in DNA repair and indi-
rect roles through transcriptional regulation of DNA repair gene
expression, particularly HR genes. The transcriptional regulation of
HR factors is clinically relevant, as the most frequent category of HR
gene defects in PCa is mRNA up-regulation, indicating that PARP-1-
mediated expression of HR factors holds clinical relevance. Finally,
PARP-1-driven expression of HR factors may be a potential deter-
mining factor in the anti-cancer effects of PARP-1 suppression
through enhancing or inducing BRCA-ness.
Discussion
Discernment of the molecular mechanisms underlying tumor
progression and therapeutic response is critical for the development
and proper utilization of treatment strategies in the management of
cancer. This study reveals that PARP-1 functions are associated with
◀ Figure 5. PARP-1 controls of HR factor availability is associated with modulation of the chromatin context of E2F1 function.A Left: Data generated as described above in Fig 2 were used to generate a heatmap of homologous recombination (HR) gene expression after the indicated
treatment regimens. Middle: Selected GSEA MSigDB Oncogenic Signature pathways are shown. Right: Data generated as described above in Fig 2 were compared to
a previously described HR deficiency transcriptional profile (Peng et al, 2014, Nature Communications). This profile was derived by independently silencing either
BRCA1, RAD51, or BRIP1, followed by transcriptional analyses. The union of these three data sets was used to generate the signature. Cutoffs for comparison were a
P value < 0.05, and fold change of 1.5. Venn diagrams shows the overlapping and non-overlapping genes of both down- (top) and up-regulated (bottom) genes in
the previously defined HR deficiency signature, and the PARPi-responsive transcriptome.
B Left: C4-2 cells were treated as depicted in Fig 2. Data are depicted as mean  standard deviation of three independent biological experiments. Statistical
significance was determined by two-tailed Student’s t-test where *P < 0.05, **P < 0.01. BRCA2, P = 0.0046; RAD51, P = 0.0151; XRCC3, P = 0.0341; TOP3A,
P = 0.04988. Right: C4-2 cells were treated as depicted in Fig 2 and immunoblotted with the indicated antisera. Quantifications shown below each band.
C Athymic nude mice were injected with C4-2 cell mixed with matrigel. Once tumors became 100 mm3, mice were treated with either vehicle control or veliparib.
Seventy-two hours later, tumors were harvested, RNA was isolated and used for qPCR quantification of the indicated transcripts. Data are depicted as log2 absolute
gene regulation of veliparib samples compared to control samples,  standard deviation of three independent xenograft tumors.
D Prostatectomy tissue (n = 6) was cultured as previously described, and treated with either vehicle control or veliparib for 6 days. RNA was then harvested from the
tissues and used for qPCR quantification of the indicated transcripts. Data are depicted as log2 absolute gene regulation of veliparib samples compared to control
samples. Each individual tissue is depicted by a separate bar color. Statistical analyses were performed by Wilcoxon signed rank test.
E C4-2 cells were treated as depicted in Fig 2. ChIP was performed using the indicated antisera, and the subsequent DNA was isolated and used in qPCR product
using primers designed to amplify the indicated genomic loci: BRCA2 enhancer, RAD51 promoter, or TOP3A promoter. Data are depicted as mean  standard
deviation of three independent biological experiments. Statistical significance was determined by two-tailed Student’s t-test where *P < 0.05, **P < 0.01. BRCA2
locus: E2F1 ChIP, P = 0.0308; PARP-1 ChIP, P = 0.0488; Pol II ChIP, P = 0.0471; AcH4 ChIP, P = 0.0081. RAD51 Promoter E2F1 ChIP, P = 0.7739; PARP-1 ChIP,
P = 0.0366; Pol II ChIP, P = 0.0767; AcH4 ChIP, P = 0.1378. TOP3A promoter: E2F1 ChIP, P = 0.0074; PARP-1 ChIP, P = 0.0500; Pol II ChIP, P = 0.0199; AcH4 ChIP,
P = 0.0158.
F, G C4-2 cells treated with 2.5 lM veliparib (Vel.) or vehicle control (Veh.) for 24 h. Cells were then harvested, lysed, and differentially centrifuged as described in the
Material and Methods section, resulting in a soluble fraction (Sol.; GAPDH serves as control) or a chromatin-tethered fraction (Teth.; histone H4 serves as control).
Immunoblots were performed for the indicated proteins.
Source data are available online for this figure.
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PCa progression, mediated in part by transcriptional events. Key
findings include the following: (i) PARP-1 enzymatic activity is
elevated as a function of PCa progression and is associated with
poor outcome; (ii) elevated PARP-1 function in advanced CRPC is
not associated with increased PARP-1 expression or correlated with
DNA DSBs; (iii) PARP-1-regulated transcriptional events are also
elevated as a function of PCa progression; (iv) PARP-1 was identi-
fied as a major regulator of E2F1 signaling, distinct from those
impacted by cell cycle modulation; (v) PARP-1 selectively regulates
E2F1-mediated expression of factors governing HR; and (vi)
Suppression of PARP-1 can induce BRCA-ness through limiting DNA
repair factor availability. Together, these data support a model in
which both the enzymatic and transcriptional regulatory function of
PARP-1 are elevated as a function of PCa progression to support
E2F1-mediated HR gene expression. These studies not only further
solidify PARP-1 as a therapeutic target in the management of PCa,
but nominate PARP-1 activity as a potential biomarker, and PARP-1
inhibition as a mechanism to induce or enhance BRCA-ness.
Data reported herein indicate that both the enzymatic activity
and transcriptional regulatory functions of PARP-1 are elevated as a
function of PCa progression. These data are consistent with a previ-
ous observation that PARP-1 enzymatic activity is elevated in cell
line models of CRPC when compared to HT-sensitive models
(Schiewer et al, 2012). Additionally, these observations align with
studies demonstrating that PARP-1 and PAR are elevated in PCa
compared to benign prostatic hyperplasia in a Chinese cohort (Wu
et al, 2014) and that PARP-1 protein is elevated in cases of primary
PCa as compared to normal controls (Salemi et al, 2013). In other
tumor types, elevated PARP-1 mRNA is associated with poor prog-
nosis in gliomas (Li et al, 2016), PARP-1 mRNA is elevated in colon
carcinoma when compared to adenoma (Dziaman et al, 2014),
PARP-1 gene expression is associated with lymph node spread of
malignant pleural mesothelioma (Walter et al, 2016), and PARP-1
mRNA and protein are elevated in endometrial adenocarcinoma (Bi
et al, 2013). Both PARP-1 mRNA and protein are highly expressed
in small cell lung cancer (Byers et al, 2012), but PARP-1 protein has
been shown to associate with longer PFS in limited-stage small cell
lung cancer (Kim et al, 2014). High PARP-1 protein is associated
with shorter survival in soft tissue sarcomas (Kim et al, 2016), poor
prognosis in gastric cancer (Park et al, 2015); is an independent
prognostic factor for decreased PFS and OS in high-grade serous
ovarian carcinoma (Gan et al, 2013); is associated with higher
grade, ER negativity, and TNBC, as well disease-free and overall
survival in operable invasive BrCa (Rojo et al, 2012); and is associ-
ated with poor prognosis in oral squamous cell carcinoma (Mascolo
et al, 2012). Additionally, PARP-1 protein is higher in triple negative
breast cancer (TNBC) specimens than in non-TNBC breast cancers,
and high PARP-1 expression is associated with worse PFS in TNBC
(Zhai et al, 2015). Combined, these studies indicate that elevated
PARP-1 occurs in many tumor types, and may have prognostic
value. Data shown herein provide some of the first evidence that
PARP-1 hyperactivation is associated with disease progression, inde-
pendent of DNA damage markers.
The underlying mechanisms that lead to elevated PARP-1 func-
tion in CRPC do not appear to be associated with elevated DNA
DSBs or increased PARP-1 protein expression, and as such, efforts
are ongoing to determine the molecular drivers and biological
consequence of elevated PARP-1 enzymatic activity in CRPC. One
clue may lie in the observation that castration alters not only PAR
levels, but also NAD+ and other PAR-related metabolites in murine
kidneys (Gartemann et al, 1981). Interestingly, high PARP activity is
associated with platinum sensitivity and improved PFS in epithelial
ovarian cancer (EOS; Veskimae et al, 2016), and PARP-1 positivity
is associated with higher grade and complete response to first-line
chemotherapy in EOS (Godoy et al, 2011), further suggesting that
assessing PARP-1 activity has potential as a meaningful biomarker.
The underlying mechanisms that drive heightened PARP-1 activity
as a function of PCa progression may be due to deregulated NAD+
production, since NAD+ is the substrate for PARP-1 production. It
has previously been reported that transcriptional regulation by
PARP-1 is affected by recruitment of an NAD+ synthase enzyme
(NMNAT-1; Zhang et al, 2012). However, there are several other
enzyme involved in NAD+ production, and each demonstrate some
patient-derived alterations in human malignancy. There are also
unexplored patient-derived alterations in PARP-1 itself, which may
affect PARP-1 activity. Furthermore, poly(ADP-ribose) glycohydro-
lase (PARG), which hydrolyzes PAR moieties, harbors patient-
derived alterations of unknown relevance, which may impact PARP-
1 activation status by differentially regulating PAR levels. It has
recently been reported that PARG impacts the response to PARPi in
models of pancreatic cancer (Chand et al, 2017). Irrespective of the
mechanism(s) by which PARP-1 is hyperactivated in advanced PCa,
studies described herein yield novel insights into the downstream
functions of elevated PARP-1 activity.
While the expression and enzymatic activity of PARP-1 are altered
in several tumor types, delineation of the transcriptional targets of
PARP-1 in PCa models revealed that not only is HR gene expression
is regulated by PARP-1 activity, the expression of HR genes is
elevated during prostate transformation. These data suggest that
PARP-1-mediated HR gene expression may promote aggressive
phenotypes. Conversely, PARP-1 inhibitors may induce BRCA-ness
(in HR-competent tumors) or enhance BRCA-ness in HR-deficient
tumors. This is consistent with a previous report that demonstrated
that TGFb signaling in wild-type BRCA1/2 breast cancers down-regu-
lates HR gene expression, and renders breast cancer cells more sensi-
tive to PARPi (Liu et al, 2014). There is also evidence that BRCA2 can
◀ Figure 6. Altered HR factor expression is prevalent in human PCa and is enriched during disease progression.A The CBioportal was used to query the DNA and RNA HR gene alterations found in the TCGA primary PCa data set. HR genes queried were BRCA1, BRCA2, RAD51,
MRE11A, RAD50, NBN, RBBP8, EXO1, RPA1, RPA2, RPA3, XRCC3, BLM, RMI1, RMI2, TOP3A, GEN1, SLX4. Default settings were used.
B Expression levels of indicated HR pathway genes in primary PCa vs. normal patient samples. Violin plots represent FPKM normalized counts obtained from matched
tumor and normal RNA-Seq data from TCGA (n = 52) with P values generated using paired t-tests. Notch is the median, length of notch is 95% confidence interval,
and whiskers are 1.5 times the interquartile range from the hinge.
C The CBioportal was used to query the DNA and RNA HR gene alterations as above using the PCF-SU2C advanced PCa data set.
D The CBioportal was used to query the DNA and RNA HR gene alterations as above using the PCF-SU2C advanced PCa data set, and the data are presented on a per
patient basis.
ª 2018 The Authors EMBO Molecular Medicine 10: e8816 | 2018 13 of 20
Matthew J Schiewer et al PARP-1 impinges on DDR gene expression EMBO Molecular Medicine
AB
C
Figure 7. PARP-1 regulates DNA repair factor availability and DNA repair competency.
A, B (A) Indicated cell lines were transfected with indicated constructs and treated with veliparib. Cell growth and (B) DDR via cH2AX was assessed. Data represent
median  standard deviation of independent biological replicates. Control transfected and vehicle control treated cells are set to 1. *P value < 0.05,
**P value < 0.01, ***P < 0.001. Statistical significance was determined by two-tailed Student’s t-test. LNCaP cell growth: Control transfection, P = 0.0220; BRCA1
transfection, P = 0.67787; BRCA2 transfection, P = 0.4676. C4-2 cell growth: Control transfection, P = 0.0354; BRCA1 transfection, P = 0.1638; BRCA2 transfection,
P = 0.2519. 22Rv1 cell growth: Control transfection, P = 0.0039; BRCA1 transfection, P = 0.1085; BRCA2 transfection, P = 0.2781. LNCaP cH2AX: Control transfection,
P = 0.0008; BRCA1 transfection, P = 0.9035; BRCA2 transfection, P = 0.4685. C4-2 cH2AX: Control transfection, P = 0.0009; BRCA1 transfection, P = 0.6362; BRCA2
transfection, P = 0.4217. 22Rv1 cH2AX: Control transfection, P < 0.0001; BRCA1 transfection, P = 0.4698; BRCA2 transfection, P = 0.4937.
C Graphical abstract of data presented herein. TF = transcription factor.
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be post-transcriptionally regulated in PCa by the lncRNA PCAT-1
(Prensner et al, 2014). Another pharmacological approach to gener-
ating BRCA-ness through transcriptional regulation has been
reported through use of histone deacetylase inhibitors in breast
cancer cells (Wiegmans et al, 2015), which has also been examined
in PCa (Chao & Goodman, 2014). Furthermore, in response to hypox-
ia, a dynamic E2F switch occurs, in which E2F1 is replaced by E2F4
at the BRCA1 promoter, thus causing gene repression and transcrip-
tionally regulated BRCA deficiency (Bindra et al, 2005). Irrespective
of the mechanism that leads to reduced HR gene expression, means
to accomplish this may be of benefit given the frequency with which
these genes are up-regulated at the mRNA level as a function of PCa
progression, and PARP-1 suppression appears to be capable of signifi-
cantly limiting HR gene expression in BRCA wild-type PCa. Whether
this is unique to either PCa in specifically or BRCA1/2 wild-type
tumor cells in general is an area of active interest.
Identification of PARP-1 as a regulator of E2F1 transcriptional
function in PCa, specifically with regard to regulation of HR gene
expression, sheds new light as to the molecular impact of PARP-1
function in cancer. PARP-1 regulation of E2F1 function is consistent
with previous studies which demonstrate that PARP-1 regulates
E2F1 transcriptional activity with respect to driving cellular prolifer-
ation (Simbulan-Rosenthal et al, 1998, 2003; Leger et al, 2016).
Furthermore, PARP-1 has been reported to be involved in the regu-
lation of E2F1-induced apoptosis (Kumari et al, 2015). Data
presented herein demonstrate that PARP-1 resides at regulatory loci
of E2F1 target HR genes, and blocking PARP-1 enzymatic activity
consistently reduced PARP-1 residency consistently at each target
locus investigated. The effect of PARP-1 function on E2F1 residency
appeared to be context-dependent, but at each locus investigated,
the recruitment of RNA polymerase II and enrichment of an epige-
netic marker of active transcription (acetylated histone H4) were
dependent upon PARP-1 enzymatic activity. Furthermore, PARP-1
suppression appears to regulate RB activity, either directly or indi-
rectly, which may contribute to E2F1 modulation. Ongoing studies
are have been designed to investigate the mechanisms by which
PARP-1 impinges upon the transcriptional repressive functions of
RB. These data suggest that PARP-1 functions to regulate a permis-
sive chromatin state for transcriptional activation of HR genes by
E2F1. This is likely based on the chromatin compaction/relaxation
capacity of PARP-1 function, and subsequent function of epigenetic
writers/readers, such as histone acetyltransferases. Future studies
are designed to investigate the mechanisms by which PARP-1 regu-
lates E2F1-driven transcriptional activation in PCa.
Finally, findings herein provide insights into novel biomarkers of
potential clinical use in PCa, which is of critical importance given
the lack of clinical biomarkers with utility in predicting PCa progres-
sion or therapeutic response, and the clinical data that indicate that
PARPi responsiveness is not necessarily linked to HR status (Fong
et al, 2009; Audeh et al, 2010; Gelmon et al, 2011; Kaye et al, 2012;
Sandhu et al, 2013; Coleman et al, 2015; Mirza et al, 2016), includ-
ing in PCa (Mateo et al, 2015; Clarke et al, 2018). This held true in
the Phase III NOVA trial (Mirza et al, 2016), in which patients with
platinum-sensitive recurrent ovarian cancer receiving niraparib (a
PARPi) maintenance therapy had increased progression-free
survival (PFS) compared to placebo control, irrespective of BRCA1/
2 mutational or HR deficiency status. Analyses of clinical samples
demonstrated that PARP-1 enzymatic activity is elevated as a
function of PCa progression, and that high PARP-1 activity strongly
correlated with decreased progression-free survival, implicated
PARP-1 as a driver of lethal malignant phenotypes. Strikingly, this
elevation in PARP-1 enzymatic activity in advanced CRPC was not
associated with either higher expression of PARP-1 itself, or with
increased evidence of DNA DSBs, which are known to activate
PARP-1 enzymatic function, implying tumor cells may select for
higher PARP-1 function through other mechanisms. Regardless,
studies herein suggest that PARP-1 enzymatic output may be a
novel biomarker of PCa aggressiveness or potential to progress to
CRPC. Furthermore, defining the PARP-1-dependent transcriptome
in PCa models revealed that the targets of PARP-1 transcriptional
regulation, including HR genes, are also elevated as a function of
PCa progression in clinical data sets. These data suggest that a tran-
scriptional profile of PARP-1 effectors has the potential to be a
biomarker of PCa progression. Current investigation into whether
this transcriptional profile, or PARP-1 enzymatic output, has utility
in predicting therapeutic response is ongoing. While PARPi is in
clinical development for PCa management, the clinical value of
targeting PARP-1 for the prevention of CRPC development, and
progression in other tumor types, should be evaluated.
In sum, the studies herein reveal fundamental new knowledge of
PARP-1 function in malignancy. The data presented are impactful in
cancer, as PARP-1 activity is increased as a function of disease
progression and is associated with poor outcomes. These novel find-
ings have the potential to impact cancer therapy, based on the
discovery that PARP-1 suppression has the capacity to induce or
enhance BRCA-ness through regulation of DNA repair factor
availability.
Materials and Methods
Standard immunohistochemistry
Tissue microarrays (TMAs) of primary PCa were provided by Dr.
Kelly (TJU), and the TMAs of mCRPC were provided by Dr. Visako-
rpi (U. Tampere). TMAs were deparaffinized in xylene, washed in
decreasing quantities of EtOH, followed by a water wash. Antigen
retrieval was done in sodium citrate buffer with boiling. Endoge-
nous peroxidase was blocked using H2O2, background was blocked
with mouse serum, and tissues were covered in a 1:500 dilution of
mouse monoclonal anti-PAR antibody (Trevigen, Gaithersburg, MD,
USA) then incubated overnight at 4°C. Slides were then washed
with PBS and developed using the Vectastain Elite ABC Mouse
IgG Kit (Vector Laboratories, Burlingame, CA, USA) according to
manufacturer’s specifications and the Liquid DAB Substrate Kit
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s specifi-
cations. Slides were then counterstained using hematoxylin by stan-
dard methods and washed in increasing EtOH concentrations
followed by xylene, and then, coverslips were mounted. Slides were
then scored blindly for both PAR intensity and PAR percent positiv-
ity by a board-certified pathologist (Dr. Parsons, TJU).
Multiplexed, fluorescent immunohistochemistry
Tissue microarray slides were stained using the OPALTM multiplex
fluorescent staining system from PerkinElmer (PerkinElmer cat. no.
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NEL794B001KT). Immunofluorescent detection of pcH2AX(Ser139;
CST #2577) was carried out with the first using a 1:200 dilution,
followed by PARP-1 (Active Motif #39559) using a 1:100 dilution
and PAR (Trevigen Inc., 4335-AMC-050) using a 1:200 dilution. The
TMA slide was first blocked with 3% H2O2 for 10 min, then treated
with animal-free protein blocker (Vector Laboratories cat. no. SP-
5030) for 15 min, and then incubated overnight at 4°C with the
pcH2AX primary antibody diluted in Antibody Dilution Buffer (Ven-
tana Medical Systems cat. no. ADB250). The next day, the TMA
slide was incubated with EnVision+ System—HRP labeled polymer
goat anti-rabbit secondary antibody (Dako cat. no. K4003) for
30 min at room temperature followed by incubation with OPAL-
FITC fluorophore for 10 min.
Next, the slide was loaded onto the Ventana autostainer using
the Ventana reagents for the machine. The pcH2AX antibody was
completely removed using heat retrieval with CC2 buffer, only leav-
ing the FITC fluorophore behind that was crosslinked to the tissue.
The PARP-1 antibody was applied manually, followed by manual
application of the OPLA-Cy3 reagent. Next, the PARP-1 antibody
was completely removed from the slide, leaving the Cy3 fluorophore
behind as it was crosslinked to the tissue. The final incubation
occurred with the PAR antibody and the OPAL-Cy5 fluorophore.
The slide was incubated with DAPI, washed, and coverslipped using
prolong gold as the mounting medium. No cross-reactivity in signals
was observed between antibodies, demonstrating that the removal
of the antibodies between staining cycles was complete.
Individual cores were imaged on the VectraTM 2 quantitative slide
imaging system. Non-neoplastic and cancer areas were annotated
by a pathologist resulting in 156 non-neoplastic areas, 277 primary
cancer areas, and 159 mCRPC areas. Missing cores and cores with-
out glands were excluded from the annotation. The InFormTM soft-
ware was used to obtain the gray-level staining images of individual
fluorophores. The amount of nuclear staining in individual nuclei
was measured for all four fluorophores (DAPI, FITC, Cy3, Cy5), and
intensity levels were normalized across the four TMA slides.
Normalized intensities of each fluorophore were dichotomized into
positive or negative using as a cutoff the median intensity across all
nuclei within the TMA. The percent of positive nuclei for every anti-
body was counted in benign and neoplastic glands. Alternatively,
the average expression of each fluorophore across all nuclei in each
annotated region was determined.
Cell culture and treatments
LNCaP and C4-2 cells were maintained in minimum essential media
(IMEM) supplemented with 5% FBS (heat-inactivated fetal bovine
serum). 22Rv1 cells were maintained in Dulbecco’s modified Eagle’s
media supplemented with 10% FBS. All media were supplemented
with 2 mmol/l of L-glutamine and 100 units/ml penicillin-strepto-
mycin. Veliparib was obtained from Enzo Life Sciences (Farming-
dale, NY, USA) and dissolved in DMSO and used at indicated
concentrations. For steroid-depleted conditions, cells were plated in
appropriate phenol red-free media supplemented with 5 or 10%
charcoal dextran-treated FBS (CDT) as appropriate. DHT was
dissolved in EtOH and used at indicated concentrations. Cell lines
were not cultured for longer than 6 months after receipt from their
original source, or no longer than 45 passages. Cell lines are authen-
ticated by ATCC annually.
Microarray analysis
Cells were seeded at equal density in steroid-depleted (CDT) condi-
tions then treated as indicated with as specified for 16 h; RNA was
isolated using TRIzol (Invitrogen) according to manufacturer’s spec-
ifications, and submitted for microarray analysis to the Sidney
Kimmel Cancer Center Cancer Genomics Shared Resource. Gene
expression was profiled using the Affymetrix Human Gene 1.0 ST
microarray (Santa Clara, CA, USA), with hybridization performed
using the GeneChip Hybridization Oven 645, followed by scanning
on Affymetrix Gene Chip Scanner 3000. Data preprocessing was
performed in Affymetrix Expression Console 1.1 using iterPLIER
summarization with PM-GCBG background correction and quantile
normalization.
Gene expression analysis
Cells were seeded at equal density in steroid-depleted (CDT) condi-
tions and were treated as specified; RNA was isolated using TRIzol
and cDNA generated using SuperScript III (Invitrogen). Quantitative
PCR was conducted with primers described in Appendix Table S1
and with an ABI StepOne machine and PowerSybr in accordance
with the manufacturer’s specifications.
ChIP analysis
Cells were cultured in media containing CDT for 72 h and treated as
indicated. ChIP analyses and qPCR were conducted as previously
described (60), using primers described in Appendix Table S1.
Xenograft analysis
Four-week-old male BALB/c nu/nu mice were purchased from
Charles River, Inc. C4-2 (2 × 106 cells) were resuspended in 100 ll
of saline with 50% Matrigel (BD Biosciences) and were implanted
subcutaneously into the flank of the mice. All tumors were staged
for 4 weeks before starting the drug treatment. For assessment of
in vivo gene expression, tumors from mice were treated with a
single dose of veliparib (100 mg/kg via oral gavage) and harvested
72 h after treatment. Tissue was harvested at indicated after 6 days
RNA was isolated using TRIzol. No statistical methods were used
for animal sample size estimate, and no blinding was done. Animals
were randomized into the two treatment regimens via coin flip.
Mice were housed in standard conditions. All animal work was
done in compliance with the regulations set forth by the Jefferson
University IACUC.
Chromatin tethering assays
C4-2 cells were treated with either 2.5uM veliparib or vehicle
control, then harvested and processed 24 h later as previously
described (Schiewer et al, 2012).
Human prostate tumor ex vivo culture
Human prostate ex vivo explant cultures were conducted as previ-
ously described (de Leeuw et al, 2015). Briefly, fresh tissue was
obtained from a pathologist immediately following radical
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prostatectomy. The de-identified specimens were processed under a
laminar flow hood, using sterile technique, and transported to the
lab in IMEM on ice. The Thomas Jefferson University Institutional
Review Board has reviewed this procurement protocol and deter-
mined this research to be in compliance with federal regulations
governing research on de-identified specimens and/or clinical data
[45 CFR 46.102(f)]. The following procedures were conducted under
sterile tissue-culture conditions. Veterinary dental sponges (Novartis
Cat. #96002) were placed in 12-well plates and soaked in 500 ml
media (IMEM supplemented with 5% heat-inactivated FBS, hydro-
cortisone, insulin from bovine pancreas, and 100 units/ml peni-
cillin-streptomycin) and appropriate treatment (either vehicle
control or 2.5 lM veliparib) for 5–10 min at 37°C. Tissue was
placed into the lid of a 10-cm plate and dissected into 1-mm3 pieces
with a scalpel. Three pieces of tissue were placed on each sponge,
using sterile tweezers or forceps. Plates were placed in an incubator
at 37°C and 5% CO2. Media were replaced every day with appropri-
ate treatment. Tissue was harvested at indicated after 6 days RNA
was isolated using TRIzol.
While there was no clinical investigation reported in this study,
informed consent was obtained from all subjects and that the exper-
iments conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report.
Cell growth assays
Cells were seeded at equal densities, treated as indicated, and
harvested at 96 h. At the time of harvest, cell number was deter-
mined using trypan blue exclusion and a hemocytometer.
Antibodies and immunoblotting
Protein isolation and immunoblotting were conducted as previously
described (Knudsen et al, 1998), using antisera described in
Appendix Table S1.
Data availability
The data sets produced in this study are available in the following
databases: Microarray data: Gene Expression Omnibus GSE118222
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118222).
Expanded View for this article is available online.
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